TY - JOUR
T1 - The human G147D-protein phosphatase 1 inhibitor-1 polymorphism is not associated with altered clinical characteristics in heart failure
AU - Chen, Guoli
AU - Zhou, Xiaoyang
AU - Pathak, Anand
AU - Dorn, Gerald W.
AU - Kranias, Evangelia G.
PY - 2009/1
Y1 - 2009/1
N2 - Objectives: A human protein phosphatase inhibitor-1 polymorphism, G147D (c.440G>A, p.147G>D), has been previously demonstrated to blunt the contractile responses of cardiomyocytes to β-adrenergic agonists. The present study sought to examine whether the G147D inhibitor-1 polymorphism may be associated with specific clinical characteristics of heart failure carriers. Methods: Clinical information of 963 heart failure patients was analyzed according to race, inhibitor-1 genotype, treatment with β-blockers and mortality patterns. Results: The G147D inhibitor-1 genetic variant was found almost exclusively in black subjects and its frequency was similar between normals and heart failure patients, indicating that it was not a primary risk factor for developing heart failure. Comparison of the major cardiac functional parameters and transplant-free survival patterns between carrier and noncarrier patients did not reveal any significant differences. Furthermore, echocardiographic evaluation showed similar outcomes of β-blocker treatment between G147D carriers and noncarriers. Conclusions: The present findings indicate that the human inhibitor-1 G147D polymorphism, found almost exclusively in blacks, may act as a modifier rather than risk factor in heart failure development.
AB - Objectives: A human protein phosphatase inhibitor-1 polymorphism, G147D (c.440G>A, p.147G>D), has been previously demonstrated to blunt the contractile responses of cardiomyocytes to β-adrenergic agonists. The present study sought to examine whether the G147D inhibitor-1 polymorphism may be associated with specific clinical characteristics of heart failure carriers. Methods: Clinical information of 963 heart failure patients was analyzed according to race, inhibitor-1 genotype, treatment with β-blockers and mortality patterns. Results: The G147D inhibitor-1 genetic variant was found almost exclusively in black subjects and its frequency was similar between normals and heart failure patients, indicating that it was not a primary risk factor for developing heart failure. Comparison of the major cardiac functional parameters and transplant-free survival patterns between carrier and noncarrier patients did not reveal any significant differences. Furthermore, echocardiographic evaluation showed similar outcomes of β-blocker treatment between G147D carriers and noncarriers. Conclusions: The present findings indicate that the human inhibitor-1 G147D polymorphism, found almost exclusively in blacks, may act as a modifier rather than risk factor in heart failure development.
KW - Heart failure
KW - Polymorphism
KW - Protein phosphatase inhibitor-1
UR - http://www.scopus.com/inward/record.url?scp=49049110304&partnerID=8YFLogxK
U2 - 10.1159/000151240
DO - 10.1159/000151240
M3 - Article
C2 - 18698139
AN - SCOPUS:49049110304
SN - 0008-6312
VL - 112
SP - 224
EP - 231
JO - Cardiology
JF - Cardiology
IS - 3
ER -